Elastrin Therapeutics

Executive Summary

Elastrin Therapeutics is a private biotech company developing first-in-class nanoparticle therapies to reverse vascular calcification, a root cause of peripheral artery disease, coronary artery disease, hypertension, and stroke. Its lead candidate employs a targeted nanoparticle that specifically binds to damaged elastin fibers in arterial walls, delivering a therapeutic payload that dissolves calcific deposits and restores arterial elasticity. This approach addresses an unmet need in cardiovascular disease, where current treatments only manage symptoms and fail to halt or reverse calcification. Preclinical data suggest the therapy can significantly reduce arterial stiffness and improve blood flow. With a strong intellectual property estate and a seasoned management team, Elastrin is positioned to advance its candidate toward the clinic. The company is actively seeking Series A funding to support IND-enabling studies and a first-in-human trial. If successful, Elastrin's platform could transform the treatment landscape for millions of patients with calcific arterial disease.

Upcoming Catalysts (preview)

• Q2 2026Series A Financing Close70% success
• Q4 2026IND Submission for Lead Candidate50% success
• Q3 2026Additional Preclinical Efficacy Data Release80% success